Regulatory FDA renews criticism of trial sponsors over transparency PharmaphorumThe FDA has launched a drive to get clinical trial sponsors to disclose the results of studies - even if they are negative.RegulatoryRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum The FDA has launched a drive to get clinical trial sponsors to disclose the results of studies – even if they are negative. RegulatoryRead full story Post navigation Previous: Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 UpdateNext: FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026